Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Vivesto
Deal Size : $1.0 million
Deal Type : Divestment
Kazia Sells IP And Trademarks Rights For Cantrixil Asset
Details : Vivesto is currently exploring TRX-E-002-1 (cantrixil), a potent and selective third generation benzopyran SMETI inhibitor, preclinically for the treatment of hematological cancers.
Product Name : TRXE-002-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 31, 2025
Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Vivesto
Deal Size : $1.0 million
Deal Type : Divestment
Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil
Details : Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufactur...
Product Name : TRX-E-002-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 21, 2022
Details : Oasmia will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.
Product Name : TRE-E-002-1
Product Type : Other Small Molecule
Upfront Cash : $4.0 million
January 03, 2021
Reset All
